Education
About Us
Working with TipRanks
Follow Us
Theratechnologies (TSE:TH)
:TH
TH Stock Chart & Stats
$4.47
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Acquisition PremiumThe acquisition offer from Future Pak represents a 126% premium to the closing price before the announcement, indicating a significant value proposition for shareholders.
Long-term Product SecurityPatent protection for EGRIFTA WR extends into 2033, providing long-term security for the product.
Product Launch ImpactThe launch of EGRIFTA WR is expected to allow the company to increase sales growth and maintain positive momentum.
Bears Say
Acquisition SkepticismThere is skepticism about the success of Future Pak's acquisition offer, and it is likely to fall through despite recognizing the value of the EGRIFTA franchise.
Financial Performance Challenges2Q25 fully adjusted EPS of ($0.09) missed consensus expectations of ($0.01), which may indicate financial challenges.
Revenue DisruptionAn expected one-time reduction in revenue due to a supply disruption resulted in a $10M — $12M decrease for FY25.
Theratechnologies News
TH FAQ
What was Theratechnologies’s price range in the past 12 months?
Currently, no data Available
What is Theratechnologies’s market cap?
Currently, no data Available
When is Theratechnologies’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Theratechnologies’s earnings last quarter?
Currently, no data Available
Is Theratechnologies overvalued?
According to Wall Street analysts Theratechnologies’s price is currently Undervalued.
Does Theratechnologies pay dividends?
Theratechnologies does not currently pay dividends.
What is Theratechnologies’s EPS estimate?
Theratechnologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theratechnologies have?
Currently, no data Available
What happened to Theratechnologies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Theratechnologies?
Currently, no hedge funds are holding shares in TSE:TH
Company Description
Theratechnologies
Theratechnologies Inc. is a Canadian biopharmaceutical company focused on developing and commercializing innovative therapies for patients with serious medical conditions. The company primarily operates in the biotechnology sector, specializing in the research and development of treatments for metabolic and endocrine disorders, with a particular emphasis on human immunodeficiency virus (HIV) and growth hormone deficiencies. Its core product, Trogarzo (ibalizumab-uiyk), is a monoclonal antibody approved for the treatment of HIV-1 in heavily treatment-experienced patients, highlighting the company's commitment to addressing unmet medical needs in complex patient populations.
Technical Analysis
Options Prices
Currently, No data available
---